Meet
Lisa Murphy
She / Her / Hers
Vice President
Lisa Murphy leads Avalere’s Marketing and Subscriptions teams.
In over 18 years at Avalere, she has led strategic client engagements focused on legislative and regulatory changes to the healthcare system and managed several subscription products focused on federal policy, state legislation, health reform implementation, and prescription drug formularies.
Prior to joining Avalere, Lisa was a consultant with Booz Allen Hamilton and served as a policy fellow in the office of US Senator Jean Carnahan, where she was responsible for advising the Senator on health and human services issues.
Lisa holds an MPP from Duke University and a BA in political science from the University of Richmond.
Authored Content
Graphic Design USA, a publication for graphic design professionals, recognized Avalere's annual report in its Inhouse Design Awards Competition.
Avalere is pleased to announce Sarah Alwardt, PhD as its new President.
Elizabeth Carpenter will step down as Avalere President. Sarah Alwardt will lead Avalere on an interim basis.
The IRA’s drug price negotiation policies, extended marketplace subsidies, and Part D redesign will impact investors’ current portfolios and investment strategy in the future.
CMS is proposing to update vaccine administration reimbursement rates annually and make changes to adult vaccination quality metrics, beginning in 2023.
In plan year (PY) 2022, most states continue to rely on the federal government for some or all exchange operational functions. However, 3 states have transitioned to state-based exchanges (SBEs).
In his first address to Congress, President Biden signaled that healthcare will continue to be a high priority for his administration, specifically highlighting pandemic response, drug pricing priorities (e.g., Medicare negotiation), and Affordable Care Act (ACA) enhancements.
Healthcare stakeholders face a unique set of challenges and opportunities in 2021 as we continue to respond to the COVID-19 pandemic and prepare for the political changes inherent in a new presidential administration. As we take stock of the historic events of 2020, it is important to look ahead toward the new era already coming into view.
While the Department of Health & Human Services (HHS) did not intend for proposed changes to Anti-Kickback Statute (AKS) regulations to impact commercial market drug negotiations, some state laws may indirectly lead to commercial market implications.
Healthcare spending is expected to represent 19.4% of US GDP in 2027.
Increasingly, states are taking steps to control prescription drug spending and prices.
The number of drugs health plans are required to cover in the individual and small group markets will vary dramatically by state in 2014.